Pharmaceutica Analytica Acta

Mesoporous silica nanoparticles for oral drug delivery

5^th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems

March 16-18, 2015 Crowne Plaza, Dubai, UAE

Amirali Popat

Posters & Accepted Abstracts: Pharm Anal Acta

Abstract:

Oral drug delivery occupies ~40% of total drug delivery market and will reach 100 billion USD by 2017, showing that oral drug delivery is still the most preferred route of administration for a variety of diseases. Recently, mesoporous silica nanoparticles (MSNs) have been studied as one class of the most promising nanocarriers in drug delivery. But, the research efforts are generally directed towards its application in Cancer using generic drug/dye molecules. Despite being used as a common excipient in tablets and FDA approved the use of colloidal silica for oral delivery is still in its infancy. Hence, there is imperative need for utilizing these excellent nanoparticles for targeting using oral dosage form. Here in we report variety of nanoformulations of MSNs targeting upper and lower part of gastrointestinal tract. We have shown that mesoporous silica nanoparticles can be programmed to release payload in response to pH, enzyme, or both in response to pH and enzyme in one system. This is interesting because targeting small intestine or colon and local release of cargo has been a holy grail of some of the inflammatory diseases such as Inflammatory Bowel Disease (IBD). Our novel platform technology can be utilized to target small intestine for targeting and improving the bioavailability of variety of drugs.